Ukrainian Biopharma Firm Invests €85 Million in New Romania Pharmaceutical Plant
In a major boost for Romania’s pharmaceutical and biotech sector, Ukrainian company Biopharma has announced a landmark investment of 85 million euros to build a state-of-the-art pharmaceutical production facility in western Romania. The project signals growing cross-border economic ties between the two neighboring countries and positions Romania as an increasingly attractive destination for international life-sciences investment.
A Strategic Move Across the Border
Biopharma, one of Ukraine’s leading biopharmaceutical companies specializing in plasma-derived medicinal products, confirmed that the new plant will be located in western Romania, close to the Ukrainian border. The facility is expected to be operational by late 2027, creating hundreds of skilled jobs in the region and strengthening the local pharmaceutical supply chain.
The investment comes at a time when Ukraine’s domestic pharmaceutical industry faces ongoing challenges due to the war, prompting several companies to expand production capacity into neighboring EU member states. Romania, with its EU regulatory framework, competitive operating costs, and strategic geographic position, has emerged as a natural choice for such expansion.
Romania’s Growing Appeal for Pharma Investment
Romania has been actively courting foreign direct investment in the life-sciences sector, offering tax incentives, EU funding access, and a well-trained workforce. The Biopharma project follows a broader trend of international companies choosing Romania as a manufacturing and R&D hub for Central and Eastern Europe.
Industry analysts note that the €85 million commitment is one of the largest Ukrainian investments in Romania’s pharmaceutical sector in recent years. The plant is expected to produce a range of plasma-based therapies and biosimilars for both the Romanian domestic market and export across the EU.
Economic and Community Impact
Local officials in the western Romanian region have welcomed the announcement, highlighting the potential for job creation, technology transfer, and infrastructure development. The project is expected to generate approximately 300 direct jobs once fully operational, with additional indirect employment in logistics, services, and supply chain operations.
“This investment demonstrates that Romania is open for business and ready to welcome international partners,” said a spokesperson for the local development agency. “The pharmaceutical sector is a strategic priority for our region, and we are committed to supporting projects that bring high-value employment and innovation.”
Strengthening Romania-Ukraine Economic Ties
The Biopharma investment also underscores the deepening economic relationship between Romania and Ukraine. As Ukraine continues its path toward greater European integration, cross-border business partnerships like this one are expected to play an increasingly important role in regional economic development.
With construction set to begin in the coming months, all eyes will be on this ambitious project as it takes shape — a symbol of resilience, cooperation, and the growing pharmaceutical prowess of the region.